论文部分内容阅读
2001年 7月,新的帕金森病治疗指南建议用多巴胺激动剂如 GlaxoSmithKline公司的罗匹尼罗（ropinirole,ReQuip）、Pharmacia公司的普拉克索（pramipexole,Mirapex/Sifrol）和Lilly公司的培高利特（pergolide,Celance/Permax）代替左旋多巴作为早期疾病的初始一线治疗,因为多巴胺激动剂较少引起运动不良反应。指南推荐是最初几年使用多巴胺激动剂,然后转用左旋多巴。左旋多巴通过补充脑内的多巴胺而起作用,而ReQuip和Mirapex等多巴胺激动剂直接刺激脑内的多巴胺受体。
In July 2001, a new guideline for the treatment of Parkinson’s disease suggested the use of dopamine agonists such as ropinirole (ReQuip) from GlaxoSmithKline, pramipexole (Mirapex / Sifrol from Pharmacia) and Pegliyne from Lilly Pergolide (Celance / Permax) replaces levodopa as initial first-line treatment for early-stage disease because dopamine agonists cause less adverse exercise reactions. The guide recommends using dopamine agonists in the first few years and switching to levodopa. Levodopa acts by replenishing dopamine in the brain, whereas dopamine agonists such as ReQuip and Mirapex directly stimulate dopamine receptors in the brain.